Substrate reduction therapy in Sandhoff disease: Evidence for improvement in nervous function in patients treated with miglustat

Substrate reduction therapy in Sandhoff disease: Evidence for improvement in nervous function in patients treated with miglustat

Bibliographic Details
Main Authors:	Lachmann, R, Wright, N, Parker, A, Ramaswarm, U, Coleman, M, Roos, J, Burnstein, R, Gillard, J, Harding, S, Platt, F, Wraith, J, Cox, T
Format:	Journal article
Published:	2006

Similar Items

Miglustat - A viewpoint
by: Platt, F, et al.
Published: (2003)

Substrate reduction therapy reduces brain ganglioside GM2 in neonatal Sandhoff disease mice
by: Baek, R, et al.
Published: (2005)

Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C.
by: Lachmann, R, et al.
Published: (2004)

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
by: Elstein, D, et al.
Published: (2004)

Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
by: Andersson, U, et al.
Published: (2004)

Substrate reduction therapy for glycosphingolipid storage disorders.
by: Lachmann, R, et al.
Published: (2001)

Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
by: Jeyakumar, M, et al.
Published: (2001)

The sensitivity of murine spermiogenesis to miglustat is a quantitative trait: a pharmacogenetic study.
by: Bone, W, et al.
Published: (2007)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
by: Baek, R, et al.
Published: (2008)

N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
by: Baek, R, et al.
Published: (2004)

NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
by: Jeyakumar, M, et al.
Published: (2004)

Treating lysosomal storage disorders: current practice and future prospects.
by: Platt, F, et al.
Published: (2009)

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
by: te Vruchte, D, et al.
Published: (2010)

Analysis of stored oligosaccharides in a mouse model of a glycolipid storage (Sandhoff) disease
by: Awan, F, et al.
Published: (2003)

Beneficial effects of acetyl-DL-Leucine (ADLL) in a mouse model of Sandhoff disease
by: Kaya, E, et al.
Published: (2020)

MRS reveals additional hexose N-acetyl resonances in the brain of a mouse model for Sandhoff disease.
by: Lowe, J, et al.
Published: (2005)

Circadian profiling in two mouse models of lysosomal storage disorders; Niemann Pick type-C and Sandhoff disease.
by: Richardson, K, et al.
Published: (2016)

Lysosomal storage and pathologenesis in a novel in vitro cellular model of Sandhoff disease
by: Boomkamp, S
Published: (2009)

Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
by: Denny, C, et al.
Published: (2010)

Substrate reduction therapy
by: Platt, F, et al.
Published: (2007)

Substrate reduction therapy.
by: Platt, F, et al.
Published: (2008)

Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin.
by: Pelled, D, et al.
Published: (2003)

C-branched iminosugars: α-glucosidase inhibition by enantiomers of isoDMDP, isoDGDP, and isoDAB-L-isoDMDP compared to miglitol and miglustat.
by: Jenkinson, S, et al.
Published: (2013)

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
by: Cox, T, et al.
Published: (2000)

A new surrogate marker for CNS pathology in Niemann-Pick disease type C?
by: Platt, F, et al.
Published: (2009)

Repairing the nervous system
by: Taylor, J
Published: (2004)

A cell-based drug delivery platform for treating central nervous system inflammation
by: Levy, Oren, et al.
Published: (2021)

Design, synthesis, and biological evaluation of enantiomeric beta-N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease.
by: Rountree, J, et al.
Published: (2009)

An introduction to nervous systems /
by: 252830 Greenspan, Ralph J.
Published: (2007)

The human central nervous system /
by: 266659 Nieuwenhuys, R, et al.
Published: (2008)

Substrate reduction therapy in mouse models of the glycosphingolipidoses.
by: Platt, F, et al.
Published: (2003)

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
by: Platt, F, et al.
Published: (2001)

Repair in the central nervous system.
by: Fitzgerald, J, et al.
Published: (2007)

Potassium channels in nervous tissue.
by: Aronson, J
Published: (1992)

Click chemistry extracellular vesicle/peptide/chemokine nanocarriers for treating central nervous system injuries
by: Ruan, Huitong, et al.
Published: (2023)

Iminosugar inhibitors for treating the lysosomal glycosphingolipidoses
by: Butters, T, et al.
Published: (2005)

Evolution of the vertebrate nervous system and telencephalon
by: Aboitiz, F, et al.
Published: (2007)

Plant nervous system
by: Qamaruz Zaman, Faridah, et al.
Published: (2016)

Infections of the nervous system.
by: Davies, N, et al.
Published: (2011)

Nervous system metabolism
by: Cadoux-Hudson, T, et al.
Published: (1990)